Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. ETF
  3. TCRX
TCRX logo

TCRX

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewTechnicalNews
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

TCRX News

Global Oncology Market Set for Rapid Growth

Mar 19 2026PRnewswire

Global Oncology Market Expected to Reach $748.17 Billion

Mar 19 2026Newsfilter

TScan Therapeutics Q4 Earnings Beat Expectations

Mar 04 2026seekingalpha

TScan Completes Enrollment in ALLOHA™ Trial Cohort C

Feb 26 2026Newsfilter

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

Dec 19 2025PRnewswire

GT Biopharma Advances GTB-3650 Clinical Trial to Cohort 4 with 10μg/kg/day Dosing

Dec 19 2025Newsfilter

TScan Reports 100% Relapse-Free Survival in AML Patients Treated with TSC-101 at Two-Year Follow-Up

Dec 06 2025Globenewswire

TScan's TSC-101 Shows Significant Efficacy in Cancer Treatment

Dec 06 2025Newsfilter

GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial

Dec 04 2025Newsfilter

GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial

Dec 04 2025PRnewswire

TScan Therapeutics Set to Update on Phase 1 Trial of TSC-101 for Hematologic Cancers Next Week

Dec 04 2025NASDAQ.COM

TScan Hosts KOL Event to Discuss ALLOHA Trial Data and Market Opportunities

Dec 03 2025Globenewswire

TScan Hosts KOL Event to Discuss ALLOHA Trial Data and Market Opportunities

Dec 03 2025Newsfilter

Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain

Dec 03 2025NASDAQ.COM

TScan Therapeutics, Inc. Reports Wider Q3 Loss, Yet Surpasses Expectations

Nov 12 2025NASDAQ.COM

Kimberly-Clark Analyst Changes Stance; Check Out Tuesday's Top 5 Downgrades

Nov 04 2025Benzinga